Latest News

Amid hydroxychloroquine hopes, lupus patients face shortages


 

For almost a quarter century, Julie Powers, a 48-year-old non-profit professional from Maryland, has been taking the same medication for her lupus — and until recently, she never worried that her supply would run out. Now she’s terrified that she might lose access to a drug that prevents her immune system from attacking her heart, lungs, and skin. She describes a feeling akin to being underwater, near drowning: “That’s what my life would be like,” she said. “I’ll suffocate.”

Powers’ concerns began roughly a week ago when she learned that her lupus drug, hydroxychloroquine (hi-DROCK-see-KLORA-quin), may be helpful in the treatment of Covid-19, the illness caused by the SARS-CoV-2 virus now racing across the planet. The medication was already being used around world to treat Covid-19 patients, but evidence of its effectiveness was largely anecdotal. Then, on March 16, a renowned infectious disease specialist, Didier Raoult, announced the results of a small clinical trial in France showing that patients receiving a combination of hydroxychloroquine and the common antibiotic azithromycin had notably lower levels of the virus in their bloodstream than those who did not receive the medication.

Upon hearing this news — and anticipating a possible drug shortage — Powers called her rheumatologist that same day and requested a prescription for a refill. She was lucky to get it.


In the last week, this once obscure drug has been thrust into the national spotlight with everyone from doctors, to laypeople, to the U.S. president weighing in. The attention has so dramatically driven up demand that pharmacists are reporting depleted stocks of the drug, leaving many of the roughly 1.5 million lupus patients across the country unable to get their prescriptions filled. They now face an uncertain future as the public clings to one of the first signs of hope to appear since the coronavirus began sweeping across the U.S.

But scientists and physicians caution that this hope is based on studies that have been conducted outside of traditional scientific timelines. “The paper is interesting and certainly would warrant future more definitive studies,” Jeff Sparks, a rheumatologist and researcher at Harvard Medical School, said of the French study. “It might even be enough data to use the regimen off-label for sick and hospitalized patients.

“However,” he added, “it does not prove that the regimen actually works.”

This has not stopped widespread promotion of the drug cocktail — including by U.S. President Donald Trump, who has helped to stoke demand for hydroxychloroquine by invoking it during his daily coronavirus press briefings. In a tweet on , the president described the regimen as possibly one of the “biggest game changers in the history of medicine.” (Anthony Fauci, the infectious disease expert spearheading the U.S. response to the coronavirus pandemic, called the evidence for the treatment anecdotal. “You really can’t make any definitive statement about it,” he told reporters March 21.)


Despite efforts to pin blame for the shortages on Trump alone , however, hydroxychloroquine scarcity was already setting in weeks ago, as doctors began responding on their own to percolating and preliminary research. Some evidence suggests that many doctors are now writing prescriptions prophylactically for patients with no known illness — as well as for themselves and family members — prompting at least one state pharmacy board to call an emergency meeting , scheduled for Sunday morning. The board planned to bar pharmacists from dispensing chloroquine or hydroxychloroquine for anyone other than confirmed Covid-19 patients without approval of the board's director.

Pages

Recommended Reading

20% of U.S. COVID-19 deaths were aged 20-64 years
MDedge Psychiatry
Feds tout drug candidates to treat COVID-19
MDedge Psychiatry
Match Day 2020: Online announcements replace celebrations, champagne
MDedge Psychiatry
COVID-19 prompts ‘lifesaving’ policy change for opioid addiction
MDedge Psychiatry
DIY masks: Worth the risk? Researchers are conflicted
MDedge Psychiatry
New ASAM guideline released amid COVID-19 concerns
MDedge Psychiatry
Emergency Rule: Docs can bill for telehealth and COVID-19 tests. Here’s how
MDedge Psychiatry
Preventable diseases could gain a foothold because of COVID-19
MDedge Psychiatry
Should patients with COVID-19 avoid ibuprofen or RAAS antagonists?
MDedge Psychiatry
Webinar confronts unique issues for the bleeding disorders community facing COVID-19
MDedge Psychiatry